Astrocytic TNFα regulates the behavioral response to antidepressants

Brain, Behavior, and Immunity

Volumn 44, Issue , 2015, Pages 187-194

  Duseja, Rachna ^a   Heir, Renu ^a   Lewitus, Gil M ^a   Altimimi, Haider F ^a   Stellwagen, David ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Cytokine; Depression; Desipramine; Fluoxetine; FST; TNF ; TST

Indexed keywords

DESIPRAMINE; FLUOXETINE; MESSENGER RNA; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; ANTIDEPRESSANT AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; ASTROCYTE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FORCED SWIM TEST; GENOTYPE; IMMOBILITY; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIMARY CULTURE; PROTEIN EXPRESSION; STANDARD; TAIL SUSPENSION TEST; UPREGULATION; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DRUG EFFECTS; GENETICS; IMMOBILIZATION; KNOCKOUT MOUSE; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; ASTROCYTES; BEHAVIOR, ANIMAL; DESIPRAMINE; FLUOXETINE; HINDLIMB SUSPENSION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; SWIMMING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84918551838     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.09.012     Document Type: Article

References (63)

1. Aloe L., Properzi F., Probert L., Akassoglou K., Kassiotis G., Micera A., Fiore M. Learning abilities, NGF and BDNF brain levels in two lines of TNF-alpha transgenic mice, one characterized by neurological disorders, the other phenotypically normal. Brain Res. 1999, 840:125-137.
2. Ampuero E., Rubio F.J., Falcon R., Sandoval M., Diaz-Veliz G., Gonzalez R.E., Earle N., Dagnino-Subiabre A., Aboitiz F., Orrego F., Wyneken U. Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience 2010, 169:98-108.
3. Bajenaru M.L., Zhu Y., Hedrick N.M., Donahoe J., Parada L.F., Gutmann D.H. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol. Cell. Biol. 2002, 22:5100-5113.
4. Barbon A., Caracciolo L., Orlandi C., Musazzi L., Mallei A., La Via L., Bonini D., Mora C., Tardito D., Gennarelli M., et al. Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochem. Int. 2011, 59:896-905.
5. Bartolomucci A., Palanza P., Parmigiani S., Pederzani T., Merlot E., Neveu P.J., Dantzer R. Chronic psychosocial stress down-regulates central cytokines mRNA. Brain Res. Bull. 2003, 62:173-178.
6. Baune B.T., Wiede F., Braun A., Golledge J., Arolt V., Koerner H. Cognitive dysfunction in mice deficient for TNF- and its receptors. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:1056-1064.
7. Bayramgurler D., Karson A., Ozer C., Utkan T. Effects of long-term etanercept treatment on anxiety- and depression-like neurobehaviors in rats. Physiol. Behav. 2013, 119:145-148.
8. Beattie E.C., Stellwagen D., Morishita W., Bresnahan J.C., Ha B.K., Von Zastrow M., Beattie M.S., Malenka R.C. Control of synaptic strength by glial TNFalpha. Science 2002, 295:2282-2285.
9. Brustolim D., Ribeiro-dos-Santos R., Kast R.E., Altschuler E.L., Soares M.B. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol. 2006, 6:903-907.
10. Bryclon L., Harrison N.A., Walker C., Steptoe A., Critchley H.D. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol. Psychiatry 2008, 63:1022-1029.
11. Cai X., Kallarackal A.J., Kvarta M.D., Goluskin S., Gaylor K., Bailey A.M., Lee H.K., Huganir R.L., Thompson S.M. Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression. Nat. Neurosci. 2013, 16:464-472.
12. Capuron L., Hauser P., Hinze-Selch D., Miller A.H., Neveu P.J. Treatment of cytokine-induced depression. Brain Behav. Immun. 2002, 16:575-580.
13. Cattaneo A., Gennarelli M., Uher R., Breen G., Farmer A., Aitchison K.J., Craig I.W., Anacker C., Zunsztain P.A., McGuffin P., Pariante C.M. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013, 38:377-385.
14. Cerri A.P., Arosio B., Viazzoli C., Confalonieri R., Teruzzi F., Annoni G. 308(G/A) TNF-alpha gene polymorphism and risk of depression late in the life. Arch. Gerontol. Geriatr. 2009, 49(Suppl. 1):29-34.
15. Chung H.S., Kim H., Bae H. Phenelzine (monoamine oxidase inhibitor) increases production of nitric oxide and proinflammatory cytokines via the NF-kappaB pathway in lipopolysaccharide-activated microglia cells. Neurochem. Res. 2012, 37:2117-2124.
16. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 2005, 29:571-625.
17. Czeh B., Di Benedetto B. Antidepressants act directly on astrocytes: evidences and functional consequences. Eur. Neuropsychopharmacol. 2013, 23:171-185.
18. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-57.
19. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 1995, 121:66-72.
20. Diamond M., Kelly J.P., Connor T.J. Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur. Neuropsychopharmacol. 2006, 16:481-490.
21. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
22. Farley S., Apazoglou K., Witkin J.M., Giros B., Tzavara E.T. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int. J. Neuropsychopharmacol. 2010, 13:1207-1218.
23. Fiore M., Probert L., Kollias G., Akassoglou K., Alleva E., Aloe L. Neurobehavioral alterations in developing transgenic mice expressing TNF-alpha in the brain. Brain Behav. Immun. 1996, 10:126-138.
24. Golan H., Levav T., Mendelsohn A., Huleihel M. Involvement of tumor necrosis factor alpha in hippocampal development and function. Cereb. Cortex 2004, 14:97-105.
25. Jun T.Y., Pae C.U., Hoon H., Chae J.H., Bahk W.M., Kim K.S., Serretti A. Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr. Genet. 2003, 13:179-181.
26. Karson A., Demirtas T., Bayramgurler D., Balci F., Utkan T. Chronic administration of infliximab (TNF-alpha inhibitor) decreases depression and anxiety-like behaviour in rat model of chronic mild stress. Basic Clin. Pharmacol. Toxicol. 2013, 112:335-340.
27. Kaster M.P., Gadotti V.M., Calixto J.B., Santos A.R., Rodrigues A.L. Depressive-like behavior induced by tumor necrosis factor-alpha in mice. Neuropharmacology 2012, 62:419-426.
28. Kessler R.C., Angermeyer M., Anthony J.C., De Graaf R., Demyttenaere K., Gasquet I., De Girolamo G., Gluzman S., Gureje O., Haro J.M., et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry 2007, 6:168-176.
29. Kreisel T., Frank M.G., Licht T., Reshef R., Ben-Menachem-Zidon O., Baratta M.V., Maier S.F., Yirmiya R. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol. Psychiatry 2014, 19:699-709.
30. Krugel U., Fischer J., Radicke S., Sack U., Himmerich H. Antidepressant effects of TNF-alpha blockade in an animal model of depression. J. Psychiatr. Res. 2013, 47:611-616.
31. Kuprash D.V., Tumanov A.V., Liepinsh D.J., Koroleva E.P., Drutskaya M.S., Kruglov A.A., Shakhov A.N., Southon E., Murphy W.J., Tessarollo L., et al. Novel tumor necrosis factor-knockout mice that lack Peyer's patches. Eur. J. Immunol. 2005, 35:1592-1600.
32. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
33. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav. Pharmacol. 1997, 8:523-532.
34. Malynn S., Campos-Torres A., Moynagh P., Haase J. The pro-inflammatory cytokine TNF-alpha regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochem. Res. 2013, 38:694-704.
35. Meyers C.A. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv. Exp. Med. Biol. 1999, 461:75-81.
36. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
37. Murphy G.M., Lee Y.L., Jia X.C., Yu A.C., Majewska A., Song Y., Schmidt K., Eng L.F. Tumor necrosis factor-alpha and basic fibroblast growth factor decrease glial fibrillary acidic protein and its encoding mRNA in astrocyte cultures and glioblastoma cells. J. Neurochem. 1995, 65:2716-2724.
38. Narita K., Murata T., Takahashi T., Kosaka H., Omata N., Wada Y. Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1159-1162.
39. O'Brien S.M., Scully P., Fitzgerald P., Scott L.V., Dinan T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 2007, 41:326-331.
40. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
41. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
42. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70:31-41.
43. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 2001, 58:445-452.
44. Reynolds J.L., Ignatowski T.A., Sud R., Spengler R.N. Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant. J. Pharmacol. Exp. Ther. 2004, 310:1216-1225.
45. Reynolds J.L., Ignatowski T.A., Sud R., Spengler R.N. An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neuroscience 2005, 133:519-531.
46. Richardson-Jones J.W., Craige C.P., Guiard B.P., Stephen A., Metzger K.L., Kung H.F., Gardier A.M., Dranovsky A., David D.J., Beck S.G., et al. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 2010, 65:40-52.
47. Sanacora G., Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol. Psychiatry 2013, 73:1172-1179.
48. Selmaj K., Shafit-Zagardo B., Aquino D.A., Farooq M., Raine C.S., Norton W.T., Brosnan C.F. Tumor necrosis factor-induced proliferation of astrocytes from mature brain is associated with down-regulation of glial fibrillary acidic protein mRNA. J. Neurochem. 1991, 57:823-830.
49. Simen B.B., Duman C.H., Simen A.A., Duman R.S. TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol. Psychiatry 2006, 59:775-785.
50. Sommer N., Loschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A., et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1995, 1:244-248.
51. Son H., Banasr M., Choi M., Chae S.Y., Licznerski P., Lee B., Voleti B., Li N., Lepack A., Fournier N.M., et al. Neuritin produces antidepressant actions and blocks the neuronal and behavioral deficits caused by chronic stress. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:11378-11383.
52. Stellwagen D., Malenka R.C. Synaptic scaling mediated by glial TNF-alpha. Nature 2006, 440:1054-1059.
53. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
54. Tuglu C., Kara S.H., Caliyurt O., Vardar E., Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 2003, 170:429-433.
55. Tynan R.J., Weidenhofer J., Hinwood M., Cairns M.J., Day T.A., Walker F.R. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav. Immun. 2012, 26:469-479.
56. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
57. Warden D., Rush A.J., Trivedi M.H., Fava M., Wisniewski S.R. The STAR*D Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 2007, 9:449-459.
58. Warner-Schmidt J.L., Vanover K.E., Chen E.Y., Marshall J.J., Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:9262-9267.
59. Xia Z., DePierre J.W., Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 1996, 34:27-37.
60. Yamada K., Iida R., Miyamoto Y., Saito K., Sekikawa K., Seishima M., Nabeshima T. Neurobehavioral alterations in mice with a targeted deletion of the tumor necrosis factor-alpha gene: implications for emotional behavior. J. Neuroimmunol. 2000, 111:131-138.
61. Yirmiya R., Pollak Y., Morag M., Reichenberg A., Barak O., Avitsur R., Shavit Y., Ovadia H., Weidenfeld J., Morag A., et al. Illness, cytokines, and depression. Ann. N. Y. Acad. Sci. 2000, 917:478-487.
62. You Z., Luo C., Zhang W., Chen Y., He J., Zhao Q., Zuo R., Wu Y. Pro- and anti-inflammatory cytokines expression in rat's brain and spleen exposed to chronic mild stress: involvement in depression. Behav. Brain Res. 2011, 225:135-141.
63. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.